TuHURA Biosciences (NASDAQ:HURA) Cut to "Sell" at Wall Street Zen

Key Points

• TuHURA Biosciences has been downgraded from a "hold" to a "sell" rating by Wall Street Zen, indicating a potential decline in investor confidence.
• Despite the downgrade, other analysts such as HC Wainwright and Brookline Capital Management continue to offer positive ratings, with an average target price of $12.67.
• The company's recent quarterly earnings showed a loss of ($0.21) EPS, missing analysts' estimates, which could contribute to the negative outlook on the stock.

Wall Street Zen lowered shares of TuHURA Biosciences (NASDAQ:HURA - Free Report) from a hold rating to a sell rating in a research note issued to investors on Saturday.

A number of other research firms also recently weighed in on HURA. HC Wainwright reaffirmed a "buy" rating and issued a $12.00 target price on shares of TuHURA Biosciences in a research report on Friday, May 16th. Brookline Capital Management raised shares of TuHURA Biosciences to a "strong-buy" rating in a research report on Monday, June 23rd. Two research analysts have rated the stock with a Strong Buy rating and three have given a Buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $12.67.

TuHURA Biosciences Stock Up 0.1%

TuHURA Biosciences stock traded up $0.00 during mid-day trading on Friday, reaching $2.59. The company's stock had a trading volume of 90,664 shares, compared to its average volume of 303,963. TuHURA Biosciences has a 12 month low of $1.80 and a 12 month high of $8.40. The business's 50 day simple moving average is $2.65 and its 200 day simple moving average is $3.05.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.07).

Institutional Trading of TuHURA Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Suncoast Equity Management boosted its holdings in shares of TuHURA Biosciences by 4.4% during the 2nd quarter. Suncoast Equity Management now owns 104,409 shares of the company's stock worth $233,000 after buying an additional 4,412 shares during the period. JPMorgan Chase & Co. bought a new stake in shares of TuHURA Biosciences during the 2nd quarter worth about $27,000. Intech Investment Management LLC bought a new stake in shares of TuHURA Biosciences during the 2nd quarter worth about $29,000. Jefferies Financial Group Inc. bought a new stake in shares of TuHURA Biosciences during the 4th quarter worth about $54,000. Finally, Invesco Ltd. bought a new stake in shares of TuHURA Biosciences during the 2nd quarter worth about $30,000. Institutional investors own 0.62% of the company's stock.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.